| Literature DB >> 29142932 |
C P Larsen1, C L Boils1, L N Cossey1, S G Sharma1, P D Walker1.
Abstract
INTRODUCTION: Ig deposits identified on renal biopsy samples by paraffin immunofluorescence that show negative staining by routine immunofluorescence on frozen tissue have become known as "masked" deposits. Membranous-like glomerulopathy with masked IgG kappa (κ) deposits is a recently recognized pattern of immune complex deposition characterized by masked deposits that show IgG κ restriction and are subepithelial and mesangial by electron microscopy. Based on the frequent presence of C3-only staining by routine immunofluorescence microscopy (IF), these cases could be misdiagnosed as C3 glomerulonephritis in the absence of paraffin immunofluorescence evaluation.Entities:
Keywords: C3 glomerulonephritis; masked deposits; membranous glomerulopathy; nephritis; proliferative glomerulonephritis with monoclonal IgG kappa deposits; renal biopsy
Year: 2016 PMID: 29142932 PMCID: PMC5678740 DOI: 10.1016/j.ekir.2016.08.012
Source DB: PubMed Journal: Kidney Int Rep ISSN: 2468-0249
Clinical characteristics of patients with membranous-like glomerulopathy with masked IgG κ deposits
| Characteristic | Value |
|---|---|
| Mean age, yr (range) | 27.5 (10−73) |
| ≤40, n (%) | 36 (88%) |
| 40−55, n (%) | 3 (7%) |
| >55, n (%) | 2 (5%) |
| Female/male, n (%) | 32 (78%)/9 (22%) |
| Race/ethnicity | |
| White, n (%) | 26 (63%) |
| Hispanic, n (%) | 9 (22%) |
| African American, n (%) | 3 (7%) |
| Other, n (%) | 3 (7%) |
| Mean serum Cr at biopsy, mg/dl (range) | 1.4 (0.5−6.4) |
| Elevated serum Cr at presentation, n (%) | 12 (29%) |
| Mean quantitative urine protein, g/24 h (range) | 3.5 (0.5−12.8) |
| Proteinuria < 1 g/24 h, n (%) | 4/40 (10%) |
| Proteinuria 1−3.5 g/24 h, n (%) | 22/40 (55%) |
| Proteinuria > 3.5 g/24 h, n (%) | 14/40 (35%) |
| Hematuria, n (%) | 35/40 (88%) |
| Positive autoimmune serologic test, n (%) | 22/40 (55%) |
| Positive ANA, n (%) | 20/38 (53%) |
| Positive dsDNA, n (%) | 9/39 (23%) |
| Positive ANA and dsDNA, n (%) | 8/40 (20%) |
| Normal C3 and C4, n (%) | 33/38 (87%) |
| Fulfills diagnostic criteria for SLE, n (%) | 1/41 (2%) |
ANA, antinuclear antibody; SLE, systemic lupus erythematosus.
Light microscopy results
| Finding | Value |
|---|---|
| Total number of glomeruli, mean n (range) | 18.8 (8−47) |
| Number of globally sclerotic glomeruli, mean n (%) | 4.3 (23%) |
| Predominant glomerular pattern | |
| Normal, n (%) | 20 (49%) |
| Mesangial hypercellularity, n (%) | 8 (20%) |
| FSGS, n (%) | 6 (15%) |
| Crescentic/focal crescentic, n (%) | 7 (17%) |
| Focal, n (%) | 4 (10%) |
| Diffuse, n (%) | 3 (7%) |
| Interstitial fibrosis | |
| None, n (%) | 18 (44%) |
| Mild, n (%) | 12 (29%) |
| Moderate, n (%) | 6 (15%) |
| Severe, n (%) | 5 (12%) |
FSGS, focal segmental glomerulosclerosis.
Figure 1Renal biopsy findings in membranous-like glomerulopathy with masked IgG κ deposits. (a) Segmental “spikes” and “holes” are present along the glomerular basement membranes by Jones methenamine silver stain (original magnification ×400). (b) Electron microscopy reveals numerous large subepithelial deposits present along the glomerular basement membrane (unstained, original magnification ×12,000). (c) Glomeruli stain negative for IgG by routine immunofluorescence on fresh tissue. (d) Glomeruli from the same case stain positive on paraffin-embedded tissue after protease digestion (direct immunofluorescence; original magnification ×400). (e) Glomeruli show staining for κ and (f) not λ on the protease-digested, paraffin-embedded tissue (direct immunofluorescence; original magnification ×400).
Immunofluorescence results
| Antibody | Immunofluorescence, frozen | Immunofluorescence, paraffin |
|---|---|---|
| IgA | 5% (1+) | 5% (1+) |
| IgM | 17% (0.9+) | 22% (0.9+) |
| IgG | 15% (0.8+) | 100% (2.9+) |
| C3 | 78% (2+) | NA |
| Kappa (κ) | 17% (1+) | 100% (2.9+) |
| Lambda (λ) | 10% (1+) | 12% (1+) |
| PLA2R (n = 29) | NA | 0 |
| THSD7A (n = 5) | NA | 0 |
Scale 0, trace, 1+, 2+, 3+.
Electron microscopy results
| Electron microscopy finding | No. of cases (% of cases), n = 41 |
|---|---|
| Subepithelial deposits | 40 (98%) |
| Mesangial deposits | 39 (95%) |
| Subendothelial deposits | 3 (10%) |
| Subepithelial “humps” | 24 (59%) |
| Hinge-region deposits | 24 (59%) |
Treatments used in patients with MGMID
| Treatment | No. of patients (% of patients), n = 27 |
|---|---|
| None | 6 (22%) |
| RAS blockade alone | 6 (22%) |
| Steroids and calcineurin inhibitor | 4 (15%) |
| Steroids and mycophenolate | 7 (26%) |
| Steroids and plaquenil | 1 (4%) |
| Steroids, calcineurin inhibitor, and rituximab | 1 (4%) |
| Steroids and azathioprine | 1 (4%) |
| Rituximab alone | 1 (4%) |
MGMID, membranous-like glomerulopathy with masked IgG κ deposits; RAS, renin−angiotensin system.
Clinical outcome by treatment
| Treatment | Complete Remission | Partial remission | Persistent disease | ESRD |
|---|---|---|---|---|
| None (n = 3) | 1 | 2 | 0 | 0 |
| RAS blockade alone (n = 6) | 3 | 0 | 3 | 0 |
| Immunosuppression (n = 15) | 7 | 2 | 6 | 0 |
| None; ESRD on presentation (n = 3) | 0 | 0 | 0 | 3 |
ESRD, end-stage renal disease; RAS, renin−angiotensin system.